Overview
Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
Status:
Unknown status
Unknown status
Trial end date:
2015-09-01
2015-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate if intravitreal Ozurdex can reduce the incidence of recurrent vitreous hemorrhage after primary pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDRP).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Anders KvantaTreatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Criteria
Inclusion Criteria:- Patients with vitreous hemorrhage undergoing PPV for PDRP
Exclusion Criteria:
- Previous PPV
- Vitreous hemorrhage of non-PDRP origin